6 best eClinical platforms for APAC clinical trials in 2026

Running a trial in the Asia-Pacific (APAC) region means navigating one of the world's most operationally complex regulatory environments — Japan's Pharmaceuticals and Medical Devices Agency (PMDA) requirements, Japan's Act on the Protection of Personal Information (APPI), China's data residency rules, and a patchwork of country-specific ICH Good Clinical Practice (GCP) implementations all come into play before you've activated a single site. Viedoc's EDC software is purpose-built to support this complexity: compliant with Japan PMDA ERES guidelines and APPI, available in 40+ languages, and used across 75+ countries with 7,000+ completed studies — including a dedicated Japan post-market surveillance (PMS) module that no other SMID-focused electronic data capture (EDC) platform offers natively. This comparison evaluates six leading eClinical platforms for APAC-operating MedTech companies and growth-stage biotech and pharma sponsors, reviewed across APAC regulatory compliance, study build speed, MedTech study design adaptability, local data requirements, and total cost of ownership.

If you're expanding into Japan, South Korea, Australia, or the broader APAC market, your platform choice determines more than data capture quality. It determines whether your regulatory submissions will hold under PMDA scrutiny, whether your post-market surveillance program can run without a bespoke system bolt-on, and whether your lean clinical team can configure and amend studies without depending on a vendor programmer.

Enterprise eClinical platforms built for US and EU Phase III trials weren't designed with APAC-specific compliance in mind. The configuration overhead, programmer dependency, and pricing structures that define platforms like Medidata Rave EDC create an operational mismatch for MedTech companies running PMS studies in Japan and for growth-stage biotech sponsors establishing their first APAC trial footprint.

Best eClinical platforms for APAC clinical trials

These six eClinical platforms represent the most frequently evaluated options for APAC-operating MedTech companies and growth-stage biotech sponsors, reviewed across regulatory compliance coverage, local market support, study build agility, and total cost of ownership.

1. Viedoc

For clinical teams operating in Japan specifically, the compliance gap between a generic EDC platform and one built for the APAC regulatory environment is material. Viedoc's EDC software, deployed across 7,000+ studies in 75+ countries, is the only SMID-focused eClinical platform with a dedicated Japan PMS module — handling booklet data collection, Kaifu workflows, query management, and PMS-specific reporting within the same application used for core EDC. No separate system, no re-training, no additional licensing process: teams select the Viedoc PMS study type directly from Viedoc Admin.

For growth-stage biotech and MedTech sponsors managing lean clinical teams, Viedoc's no-code Designer means your data managers configure studies in-house without vendor-side programmers — which translates directly to faster go-live and lower amendment turnaround in time-sensitive APAC markets. Study builds are typically completed in 2–4 weeks, and Viedoc's unlimited user seat model means adding site staff in Japan, South Korea, or Australia doesn't inflate licensing costs mid-study.

Viedoc is ISO 27001 and SOC 2 certified, compliant with FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, HIPAA, and Japan PMDA ERES guidelines, and certified under APPI for Japanese data handling. The platform delivers 99.99% uptime on Microsoft Azure, operates across 40+ languages, and provides 24/7 customer support from global offices including Japan and Southeast Asia. For APAC buyers, the Viedoc Inspection Readiness Packet (VIRP) provides structured validation documentation that supports PMDA and TGA submissions without starting from scratch.

"My experience with Viedoc has been excellent. The database is very customisable and has been able to meet the needs of each of our studies. Customer Support has been excellent with quick turnarounds and response time." — Amanda M., Sr. Clinical Program Manager

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Build speed: Study builds typically completed in 2–4 weeks
• Japan PMS: Native Japan PMS module; PMDA ERES compliant; APPI certified — unique among SMID-focused EDC platforms
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Language support: Available in 40+ languages
• Compliance: FDA 21 CFR Part 11, GDPR, EU Annex 11, HIPAA; ISO 27001 and SOC 2 certified; APPI (Japan)
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Inspection readiness: VIRP available to all customers

2. Medidata

Medidata offers Rave EDC, a cloud-based electronic data capture solution for global clinical trials. Medidata has operated in the APAC region since 2005, with offices in Japan, China, India, South Korea, Singapore, and Australia, and has developed local regulatory expertise across those markets. Rave EDC supports data capture, management, cleaning, and reporting within the broader Medidata Unified Platform, which also includes RTSM, eCOA, and safety tools. Medidata also offers Rave Lite, a focused version of Rave EDC designed for Phase I, Phase IV, and medical device post-market studies, with pre-configured implementation capabilities intended to reduce study build timelines. Study configuration typically requires vendor-side programmers, and the platform is primarily positioned for large pharma and complex Phase III registrational trials where its enterprise infrastructure is a differentiator. The APAC build cycle and programmer dependency may add lead time for leaner sponsor teams.

3. Veeva Vault EDC

Veeva offers Vault EDC as part of the Veeva Clinical Platform, which also includes CTMS, eTMF, and study start-up. Vault EDC is a cloud-based solution providing point-and-click study build, zero-downtime amendments, and bi-directional data flow to other Vault applications. The Vault Platform is hosted at SOC 1 Type II and ISO 27001 certified global data centers, with IQ and OQ validation delivered for each major release. Veeva has expanded its APAC presence and has relationships with leading APAC contract research organizations (CROs), including Tigermed and SGS CR. Vault EDC is increasingly adopted by large biopharma organizations seeking to standardize on the Vault Clinical Suite — eight of the top 20 biopharma companies have standardized new trials on the platform. For teams not already invested in the broader Vault ecosystem, the full suite's value proposition may require adoption of multiple products to realize.

4. Castor EDC

Castor EDC offers Castor CDMS, a cloud-native, no-code/low-code eClinical platform combining EDC, eCOA/ePRO, and eConsent. The platform is ISO 27001 and ISO 9001 certified, compliant with FDA 21 CFR Part 11, EU Annex 11, ICH GCP, HIPAA, and GDPR, and stores data on certified servers with configurable data residency by country. Castor reports 800+ MedTech studies delivered globally, covering pivotal trials, post-market clinical follow-up (PMCF) studies, and medical device registries. The platform supports CDISC, CE Mark, MDR, IVDR, and FDA De Novo compliance workflows, with study builds available in as little as 6–8 weeks through professional services-led implementations. Data residency and Japan PMDA ERES compliance are not explicitly confirmed on Castor's public documentation; teams requiring native Japan PMS capabilities should verify this directly.

5. Medrio

Medrio offers Medrio CDMS/EDC, a cloud-based, no-code eClinical suite that includes EDC, eCOA/ePRO, eConsent, and RTSM. The platform is compliant with FDA 21 CFR Part 11, ICH E6(R2), HIPAA, and GDPR, and supports fast study builds through point-and-click configuration. Medrio is used by pharmaceutical, biotech, and medical device sponsors and CROs, with explicit positioning for MedTech start-ups and emerging biopharma organizations. The company has approximately two decades of experience, maintains a 98% customer retention rate per its website, and provides 24/7 expert support. Medrio's APAC-specific regulatory compliance coverage — including Japan PMDA ERES and APPI — is not explicitly documented on its public-facing product pages; teams running Japan PMS studies or requiring APAC-specific regulatory certifications should confirm scope directly with Medrio.

6. Oracle Clinical One

Oracle offers Oracle Clinical One Data Collection, a cloud-based EDC platform developed from the Oracle InForm heritage and updated with AI-enabled capabilities including EHR interoperability, AI-powered RTSM, and integration with Oracle Safety One Argus. The platform supports global trials with data collection across EDC, ePRO/eCOA, and eConsent in a unified interface, and is available to APAC customers as part of Oracle's global cloud infrastructure. Oracle has a dedicated APAC clinical trials page and has published APAC-region enhancements. Clinical One is positioned for organizations seeking unified data management across large multi-site, multi-country portfolios. Implementation complexity and the legacy codebase heritage from InForm may add validation overhead for smaller teams moving from legacy on-premise deployments.

What to look for in eClinical platforms for APAC clinical trials

APAC regulatory compliance depth

APAC is not a single regulatory environment — it's a collection of distinct national frameworks operating at varying degrees of alignment with ICH GCP. Japan's PMDA operates under ERES guidelines that require specific electronic record and signature controls; APPI governs Japanese personal data handling with requirements distinct from GDPR; Australia's Therapeutic Goods Administration (TGA) applies its own GCP inspection standards; and China's National Medical Products Administration (NMPA) has specific data residency and localization requirements. A platform's marketing claim of "global compliance" doesn't confirm coverage for each of these jurisdictions. Before shortlisting, confirm which APAC regulatory frameworks your platform explicitly certifies to — and whether that certification covers the specific study types you're running, not just general EDC deployments.

The consequence of assuming compliance that isn't documented is a failed regulatory submission or a PMDA query that delays market approval by months. For Japan-operating companies in particular, platform-level ERES compliance and APPI certification aren't optional extras.

Japan post-market surveillance workflow support

Japan's PMS regulatory framework requires booklet data collection formats, Kaifu review workflows, progress management reporting, and query management structures that have no direct equivalent in Western trial designs. A generic EDC platform can approximate some of this through custom case report form (CRF) builds, but this adds configuration time, validation overhead, and ongoing maintenance burden that compounds across a multi-study PMS program.

Best-in-class for this requirement looks like a native PMS module integrated within the core EDC platform — where study designers use the same environment for PMS and interventional studies, no additional training is required, and progress management can connect to external systems through integration. Teams running more than one Japan PMS study simultaneously should weight this capability heavily: manual workarounds that are tolerable at study one become bottlenecks at study five.

Study design adaptability for non-pharma workflows

MedTech clinical programs have structural differences from interventional pharma trials — longer follow-up windows, registry designs, observational studies, PMCF requirements, and patient populations that may interact with the platform differently than trained site staff in a conventional trial setting. A platform optimized for randomized Phase II oncology studies will require significant customization to handle a 36-month medical device registry across five APAC markets.

What best-in-class looks like here is a no-code designer that supports flexible CRF architecture without requiring vendor-side programmers for every protocol amendment, combined with amendment turnaround measured in days rather than quarters. For lean MedTech teams, the cost of a vendor-dependent amendment process across a multi-year PMS program can exceed the annual platform license.

Multi-language site and patient support

APAC clinical operations span languages including Japanese, Mandarin, Korean, Vietnamese, and English — often within a single multi-country study. Sites operating in Japanese-language interfaces produce fewer data entry errors and lower query volumes; patient-reported outcome (PRO) instruments translated and validated for the local language produce more reliable data.

Evaluate language support not just at the system interface level but at the patient-facing level too. If your ePRO module doesn't support the validated local-language version of your PRO instrument, you may need a separate vendor — adding integration risk, validation burden, and cost. A platform supporting 40+ languages natively removes this as a project variable.

Data hosting and residency controls

China's Personal Information Protection Law (PIPL) and data residency requirements mean that trial data collected at Chinese sites may need to remain on China-domiciled servers. Japan's APPI has analogous implications for Japanese patient data in certain contexts. Cloud-native platforms built on global infrastructure — Azure, AWS, or Google Cloud — may have the technical capability to offer regional data residency, but this must be explicitly confirmed per jurisdiction and per study type.

For APAC-operating sponsors, failure to address data residency at contract stage can trigger mid-study remediation, regulatory queries, or IRB/ethics committee review of your data management plan. Verify hosting architecture and data residency options before signing, not after.

How to choose the right eClinical platform for APAC clinical trials

Step 1: Define your APAC regulatory surface

Before evaluating platforms, map which jurisdictions you're submitting to and which regulatory bodies will inspect your data. Japan PMDA, Australia TGA, South Korea MFDS, and China NMPA each have distinct requirements; a platform certified under one isn't automatically qualified for another. Write down the specific regulatory frameworks — ERES, APPI, PIPL, TGA GCP — and use this as your platform qualification checklist, not your feature wishlist.

Step 2: Assess your Japan PMS exposure

If Japan post-market surveillance is on your roadmap — now or within three years — this should be a hard filter at the platform selection stage, not a question for year two. The cost of migrating a PMS program mid-study to a platform with native Japan PMS support will typically exceed the cost difference between platforms. Determine now whether you need native PMS workflow support or whether a validated custom-build approach is operationally acceptable for your organization.

Step 3: Evaluate in-house configuration capability against your team structure

APAC trial programs frequently operate with smaller central data management teams than their US or EU counterparts, with higher reliance on site-level staff who may have limited EDC experience. A platform that requires vendor-side programmers for study builds and protocol amendments compounds this challenge. Evaluate whether your team can run the full study lifecycle — design, amendment, closeout — independently, and what the support model looks like outside of US/EU business hours for APAC time zones.

Step 4: Scrutinize the total validation burden

Switching eClinical platforms is costly not because of licensing differences but because of validation. Computer system validation (CSV), audit trail review, and re-training across a multi-country site network represent hundreds of hours of work — before the first patient is enrolled on the new system. Choose the platform your compliance team can validate once, maintain over a multi-year program, and inspect with confidence. Ask specifically about what validation documentation is provided out of the box, and how amendments are handled from a revalidation perspective.

Step 5: Choose a platform with the right APAC fit for your study portfolio

If you're running Japan PMS, device registries, or observational studies across multiple APAC markets, a platform built for lean-team self-service with native Japan compliance capabilities is operationally the right fit. Viedoc's EDC software and Japan PMS module are designed precisely for this profile — with the VIRP to support inspection readiness and a no-code Designer your team runs independently. Book a demo or request a proposal to see how Viedoc's APAC compliance posture maps to your study portfolio.

Frequently asked questions

What is the best eClinical platform for APAC clinical trials?

Viedoc's EDC software is the best choice for APAC-operating MedTech companies and growth-stage biotech sponsors, combining Japan PMDA ERES compliance, APPI certification, and a native Japan PMS module in a single platform that study teams can configure without vendor programmers. Viedoc is available in 40+ languages, operates across 75+ countries, and delivers study builds typically completed in 2–4 weeks. Medidata offers deep APAC infrastructure for large pharma and complex Phase III registrational trials but involves significantly greater configuration overhead. Castor EDC is a strong option for MedTech PMCF studies in regions where Japan-specific PMS workflow support isn't required.

What compliance certifications should I look for in an eClinical platform for APAC trials?

At minimum, confirm FDA 21 CFR Part 11, ICH E6(R2) GCP, ISO 27001, and SOC 2 certification. For Japan specifically, look for Japan PMDA ERES compliance for electronic record and signature controls, and APPI certification for Japanese personal data handling. If you're operating in China, confirm NMPA alignment and data residency capability on China-domiciled infrastructure. For Australia and South Korea, confirm TGA GCP and MFDS alignment respectively. Don't accept "global compliance" as a substitute for country-specific certification confirmation — especially for APAC markets where regulatory frameworks diverge materially from FDA and EMA standards.

How long does it typically take to build and deploy a clinical study on a modern eClinical platform for APAC trials?

On a modern, no-code eClinical platform, study builds for APAC trials are typically completed in 2–4 weeks for standard interventional designs, with Japan PMS studies potentially requiring additional time for booklet data collection configuration and local workflow validation. Enterprise platforms with programmer-dependent build processes can take significantly longer — up to 90 days in some configurations. For lean MedTech and growth-stage biotech teams operating in APAC time zones, the amendment turnaround speed is equally important: a platform that requires vendor-side involvement for every CRF change introduces bottlenecks in markets where regulatory queries and protocol amendments are common during active recruitment.

Which eClinical platforms support Japan post-market surveillance studies?

Viedoc's Japan PMS module is the only native, integrated PMS solution among SMID-focused EDC platforms, handling booklet data collection, Kaifu workflow management, progress management, and reporting within the same application as core EDC. It is PMDA ERES compliant and APPI certified, and requires no additional system access or separate licensing — teams select the PMS study type from Viedoc Admin. Other platforms in this comparison do not explicitly document native Japan PMS workflow support on their public-facing product pages; teams should verify scope directly before shortlisting.

What is the difference between general GCP compliance and PMDA ERES compliance?

GCP compliance — specifically ICH E6(R2) — establishes the international standard for clinical trial conduct, data integrity, and site oversight. PMDA ERES compliance is Japan-specific: it defines the requirements for electronic records and electronic signatures in clinical trial data submitted to the Japanese regulatory authority, including data traceability, audit trail completeness, access controls, and documentation standards aligned with Japan's own regulatory framework. A platform that meets FDA 21 CFR Part 11 and ICH GCP is not automatically PMDA ERES compliant — the PMDA applies distinct interpretive guidance that requires platform-level certification. For companies pursuing PMDA approval or conducting PMS studies under PMDA oversight, ERES compliance is a mandatory technical requirement, not a nice-to-have.

What eClinical platform features matter most for MedTech device studies in APAC?

For MedTech teams in APAC, the highest-value capabilities are study design adaptability for registry and observational designs, Japan PMS workflow support, lean-team self-service configuration, low IT overhead, and 40+-language support for multi-country site activation. Device studies tend to have longer follow-up windows, less standardized CRF structures, and smaller central data management teams than interventional pharma trials — which means a no-code platform your team runs independently, with amendment capability that doesn't require vendor intervention, is worth more than an enterprise platform with features you'll never use. Integration with external progress management systems and CDISC-compliant data exports for regulatory submissions are also worth evaluating early.

Making the right eClinical choice for APAC clinical trials

The global eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually — and the Asia-Pacific region is currently its fastest-growing segment, driven by trial globalization, government investment in research infrastructure, and the increasing alignment of APAC regulatory frameworks with ICH GCP standards. The platforms reviewed here range from established global enterprise incumbents with deep APAC CRO networks to lean, cloud-native options built for fast-moving sponsor and MedTech teams.

Matching platform to organizational profile in this market comes down to three variables: the regulatory jurisdictions you're operating in, the study types in your portfolio, and the size and structure of your central data management team. APAC buyers typically weight compliance credentials and vendor stability alongside speed — and for Japan-operating companies, the question of native PMS workflow support is often a disqualifying filter before the evaluation properly begins.

The validation burden of an eClinical platform switch — particularly across a multi-country APAC site network — is significant enough that choosing the wrong platform at the outset carries compounding costs well beyond the initial contract. The right question to ask in every shortlist evaluation is not which platform has the most features, but which platform can be validated once, run independently by your team, and maintained without re-engagement every time a protocol changes.

Why Viedoc is the best eClinical choice for APAC clinical trials

Viedoc is the only SMID-focused eClinical platform with a native Japan PMS module — fully integrated with Viedoc's EDC software, PMDA ERES compliant, APPI certified, and accessible without additional licensing or training for teams already using Viedoc Designer. That's a meaningful distinction when your compliance team is validating a system for multi-year PMS use across Japan.

Beyond Japan PMS, Viedoc's eClinical suite covers EDC, ePRO/eCOA, Televisit, eTMF, eSignature, and RTSM on a transparent, study-based licensing model with unlimited user seats. For growth-stage sponsors expanding into APAC, this means you're not paying per-user fees as you activate sites in Japan, South Korea, and Australia — and your data management team can configure and amend studies in-house using Viedoc's no-code Designer, without vendor programmer dependency.

The compliance credentials are documented and verifiable: ISO 27001 and SOC 2 certified, FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, HIPAA attestation, and Japan PMDA ERES. The VIRP supports PMDA and TGA inspection readiness from day one. Viedoc has operated since 2003, has delivered 7,000+ studies across 75+ countries, and provides 24/7 support from global offices including Japan.

If APAC compliance, Japan PMS workflow, and lean-team self-service are your priorities, book a demo or request a proposal and our team will walk you through how Viedoc's APAC capabilities map to your study portfolio.